Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Graft versus host inhibition. IX. Therapeutic potential of combined fetal liver and thymus cells as a universal hematopoietic stem cell source for transplantation. Final report 1 Mar 72--31 Jul 77

Technical Report ·
OSTI ID:7086128
The major accomplishment under this contract was the development and testing of a treatment model using mice to evaluate transplantation of liver and thymus cells from immunologically immature (fetal) donors as a source of hematopoietic stem cells. The following observations were made: (1) Fetal liver cells can be used as a source of hematopoietic stem cells without the complication of acute graft-versus-host disease; (2) Recovery from radiation injury was dependent on the dose of fetal liver cells transplanted; (3) Transplanting very small numbers of fetal thymus cells, in addition to liver cells, had a significant and salutary effect on recovery from radiation injury in some strain combinations, but not in others; (4) Transplantation of fetal liver cells from histoincompatible unrelated donors resulted in less delayed secondary disease mortality than did bone marrow transplants from histocompatible unrelated donors; (5) Cell yields from human embryonic tissue increased exponentially with age, and the liver:thymus ratio was 35.4:1, and (6) Fetal liver + or - thymus cells promoted recovery in lethally irradiated adult mice when given in a cell dose per kg body weight comparable to that from a human fetus at 14 weeks embryonation.
Research Organization:
Mount Sinai Medical Center, Milwaukee, WI (USA). Winter Research Lab.
OSTI ID:
7086128
Report Number(s):
AD-A-049151
Country of Publication:
United States
Language:
English